Mersana Therapeutics (NASDAQ: MRSN) stock is down 73%. The MRSN stock failure is based on the failure of its ovarian cancer drug to pass one of the many tests that are necessary before approval. As a result the company has fired half the staff - this is close to an extinction level event. “Dr. Arvin Yang, Senior Vice President and Chief Medical Officer of Mersana Therapeutics. “While the duration of response was longer than that from the dose expansion portion of UpRi's Phase 1b clinical trial, the lower bound of the confidence interval for the primary endpoint did not meet our goal of excluding a 12% ORR seen with standard-of-care single-agent chemotherapy.”
To translate that into normal language - “it didn't work like we hoped it would.”
This is the big risk in pharma development investing. There is a series of trials a drug must go through before it is approved by the FDA and can therefore go on general sale - and start earning some revenue. Phase 1 is largely about making sure it doesn't poison those taking it (we paraphrase, of course). Phase II is whether it actually works in treating the disease or symptom being targeted. Phase III is whether it has unacceptable side effects in a wider population. These can - and often are - further subdivided into Phase 1b and so on. The drug - or treatment - must pass all of these in order to be approved. The costs of testing rise dramatically as we go through the different stages. A Phase II fail is more expensive than a Phase I, a III than a II etc.

Mersana Therapeutics stock price from Google Finance
As we can see from the stock price chart there, there was an earlier problem - “The decision follows bleeding events reported from about 560 patients who received UpRi, an antibody-drug conjugate. The reason for the bleeding events remains under investigation, Mersana (MRSN) said. However, there were five (<1%) Grade 5 (fatal) bleeding events though most of the cases were low-grade. Patients in the UP-NEXT and UPGRADE-A trials can continue to receive the therapy.” The drug apparently killed five patients through bleeding out. Which we might think is conclusive. But cancer treatments - especially as here, where the treatment is for cancers resistive to the usual treatments, so the people are dying anyway - are held to different standards. If everyone's about to die anyway then we'll accept some deaths for those who might be saved, or have life extended.
The problem is that of course to be willing to carry those risks the drug must actually work. Which is the bit that Mersana seems to have failed here. They've fired half the workforce. There's $400 million in market capitalisation - at least - gone. A revival in any immediate timespan looks unlikely to us.